Received Jun 2, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | — | — |
Bexsero - second dose before 6 months; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too short in a patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (received 1st and 2nd dose in the October 2024 to February 2025 timeframe). On an unknown date, the patient received the 3rd dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too short (Verbatim: Bexsero - second dose before 6 months). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 28-MAY-2025 Health care professional unsure what to do with patients who completed Bexsero series one month apart in the October 2024 to February 2025 timeframe. Clinic was either made aware or realized dosing change in February 2025. They want to know if those patients need three doses. The patient received 3rd dose of Bexsero earlier than the recommended interval, which led to shortening of vaccine schedule.